LBX1 and neoplasm: KD prevents and treats colorectal cancer by engaging the hydroxycarboxylic acid receptor 2 with β-hydroxybutyrate, subsequently activating the homeobox only protein signaling pathway to curb colorectal cancer cell proliferation and tumor development [67].